SCHEMBL3344884

SCHEMBL3344884

Cc1c(Cc2ccc(Cl)cc2)c(=O)[nH]c2c(F)ccc(O)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.39
MAPT P10636 4/20 0.38
ALDH1A1 P00352 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
DAO P14920 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
NR3C1 P04150 1/20 0.35
P2RX3 P56373 1/20 0.35
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
PKM P14618 1/20 0.34
ERAP1 Q9NZ08 1/20 0.34
PTGES O14684 1/20 0.34
ALOX5 P09917 1/20 0.34
KDM4A O75164 1/20 0.33
KDM4C Q9H3R0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3778310 0.91 ALDH1A1 (0.39) SLC2A1MAPTALDH1A1DAOLMNA
SCHEMBL2573266 0.89 PDE3B (0.37) SLC2A1MAPTALDH1A1DAOLMNA
SCHEMBL3779299 0.89 DAO (0.40) MAPTALDH1A1MEN1KMT2ADAO
SCHEMBL3345036 0.86 PTGS2 (0.41) MAPTALDH1A1MEN1KMT2ADAO
SCHEMBL3778300 0.85 PSIP1 (0.34) MAPTALDH1A1MEN1KMT2ADAO
SCHEMBL3779905 0.84 KDM4E (0.38) MAPTALDH1A1MEN1KMT2ADAO
SCHEMBL2573298 0.84 MAPT (0.31) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL3785180 0.83 KDM4E (0.47) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL3776982 0.80 KDM4E (0.39) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL2576178 0.80 PTGDR2 (0.41) ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
WO-2010040989-A1 QUINOLIN-2-ONE COMPOUNDS ARGENTA ORAL THERAPEUTICS LIMITED (GB) 2010-04-15 WO disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 SLC2A1 3121/4885MAPT 4787/4885ALDH1A1 4201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.